Thermo Fisher Scientific Inc. $TMO Shares Sold by NORTHSTAR ASSET MANAGEMENT Co

NORTHSTAR ASSET MANAGEMENT Co cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.0% during the first quarter, Holdings Channel.com reports. The fund owned 17,307 shares of the medical research company’s stock after selling 1,099 shares during the period. Thermo Fisher Scientific comprises approximately 1.9% of NORTHSTAR ASSET MANAGEMENT Co’s holdings, making the stock its 11th biggest position. NORTHSTAR ASSET MANAGEMENT Co’s holdings in Thermo Fisher Scientific were worth $8,507,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the business. High Note Wealth LLC increased its position in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after buying an additional 29 shares in the last quarter. Swiss RE Ltd. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $28,000. JPL Wealth Management LLC acquired a new position in Thermo Fisher Scientific during the third quarter worth $28,000. Beacon Financial Strategies CORP purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at $29,000. Finally, Olistico Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $29,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.5%

NYSE TMO opened at $505.09 on Tuesday. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $401.45 and a 52 week high of $643.99. The business’s fifty day simple moving average is $473.86 and its 200-day simple moving average is $519.44. The firm has a market cap of $187.70 billion, a PE ratio of 27.77, a P/E/G ratio of 2.27 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. Thermo Fisher Scientific’s revenue was up 6.2% compared to the same quarter last year. During the same period last year, the business earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on TMO shares. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Piper Sandler initiated coverage on Thermo Fisher Scientific in a report on Thursday, June 11th. They set a “neutral” rating and a $510.00 target price for the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $620.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Finally, Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $605.09.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.